Albain KS et al. Prognostic and predictive value of the 21-gene Recurrence Score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11(1):55-65. Abstract
André F et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019;380(20):1929-40. Abstract
André F et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update — Integration of results from TAILORx. J Clin Oncol 2019;37(22):1956-64. Abstract
Corona SP et al. CDK4/6 inhibitors in HER2-positive breast cancer. Crit Rev Oncol Hematol 2017;112:208-14. Abstract
Di Leo A et al. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. NPJ Breast Cancer 2018;4;41. Abstract
Dowsett M et al. PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib. San Antonio Breast Cancer Symposium 2018;Abstract GS3-02.
Dowsett M et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11 (2 Pt 2):951s-8s. Abstract
Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;365(9472):1687-717. Abstract
Finn RS et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375(20):1925-36. Abstract
Formisano L et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun 2019;10(1):1373. Abstract
Goel S et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 2016;29(3):255-69. Abstract
Goetz MP et al. Efficacy of abemaciclib based on genomic alterations detected in baseline circulating tumor DNA from the MONARCH 3 study of abemaciclib plus nonsteroidal aromatase inhibitor. San Antonio Breast Cancer Symposium 2019;Abstract PD2-06.
Goetz MP et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35(32):3638-46. Abstract
Goetz MP et al. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies. San Antonio Breast Cancer Symposium 2017;Abstract GS6-02.
Gray R; Early Breast Cancer Trialists’ Collaborative Group. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women. San Antonio Breast Cancer Symposium 2018;Abstract GS3-03.
Hortobagyi GN et al. Breast cancer-specific mortality (BCSM) in patients (pts) with node-negative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: A SEER-genomic population-based study. San Antonio Breast Cancer Symposium 2018;Abstract P3-11-02.
Hortobagyi GN et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol 2016;34(5):419-26. Abstract
Hortobagyi GN et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375(18):1738-48. Abstract
Hurvitz S et al. Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2- breast cancer. San Antonio Breast Cancer Symposium 2016;Abstract S4-06.
Im S-A et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381(4):307-16. Abstract
Johnston S et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J Clin Oncol 2019;37(3):178-89. Abstract
Juric D et al. Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial. San Antonio Breast Cancer Symposium 2018;Abstract GS3-08.
Krop I et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 2017;35(24):2838-47. Abstract
Lok SW et al. A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer. Cancer Discov 2019;9(3):354-69. Abstract
Ma CX et al. NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res 2017;23(15);4055-65. Abstract
Mamounas EP et al. Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI). San Antonio Breast Cancer Symposium 2019;Abstract GS4-01.
Nitz U et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: Five-year data from the prospective, randomized phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat 2017;165(3):573-83. Abstract
O’Leary B et al. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 2016;13(7):417-30. Abstract
Pandey K et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. Int J Cancer 2019;145(5):1179-88. Abstract
Patnaik A et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov 2016;6(7):740-53. Abstract
Piccart MJ et al. Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X. San Antonio Breast Cancer Symposium 2019;Abstract GS4-05.
Rugo HS et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2. Ann Oncol 2014;25(4):808-15. Abstract
Sledge GW Jr et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy — MONARCH 2: A randomized clinical trial. JAMA Oncol 2019;[Epub ahead of print]. Abstract
Sledge GW Jr et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35(25):2875-84. Abstract
Sparano JA et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 2019;380(25):2395-405. Abstract
Sparano JA et al. Clinical outcomes in early breast cancer with a high 21-gene Recurrence Score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: A secondary analysis of the TAILORx randomized clinical trial. JAMA Oncol 2019;[Epub ahead of print]. Abstract
Sparano JA et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379(2):111-21. Abstract
Tolaney et al. MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer. ESMO 2019;Abstract LBA23.
Turner NC et al. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet 2017;389(10087):2403-14. Abstract
Turner NC et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 2018;379(20):1926-36. Abstract